## Zelboraf (vemurafenib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID N	UMBER:			
F YOU ARE NOT THE PATIENT OR THE PRESFOLLOWING LINK: PRIMETHERAPEUTICS.CC	CRIBER, YOU WILL NEED TO SUBMIT A PHI DI MM/NOPP PRESENTATIVE (IF APPLICABL	IGHT (LB/KG): ALLERG	QUEST WHICH CAN BE FOUND AT THE	
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATIO	N			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	OFFICE CONTACT PERSON:	
MEDICATION OR MEDICA	L DISPENSING INFORMATION	l e e		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
■ NEW THERAPY DURATION OF THERAPY (SI	RENEWAL PECIFIC DATES):	IF RENEWAL: DATE THERAPY	Y INITIATED:	

Continued on next page.



## Zelboraf (vemurafenib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:					
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO			
MEDICATION/THERAPY (SPECIFY	<b>DURATION OF THERAPY</b> (SPECIFY	RESPONSE/REASON FOR			
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
□ Melanoma					
	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A					
PRIOR AUTHORIZATION.					
Clinical Information:					
Does the patient have a diagnosis of unresectable or metastatic melanoma? ☐ Yes ☐ No					
Is the patient BRAF V600E mutation positive?* □ Yes □ No *Please provide documentation.					
If " <u>yes</u> " to the above question, will Zel	boraf (vemurafenib) be used as monoth	nerapy? □ Yes □ No			
Is the patient BRAF V600K mutation positive?* □ Yes □ No *Please provide documentation.					
Will Zelboraf (vemurafenib) be used in combination with Cotellic (cobimetinib)? ☐ Yes ☐ No					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					
Please note: Not all drugs/diagnosis are information is received.	e covered on all plans. This request may	be denied unless all required			
ATTESTATION: I attest the information	n provided is true and accurate to the be	st of my knowledge. I understand that			
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical					
information necessary to verify the accuracy of the information reported on this form.					
Prescriber Signature or Electronic I.D.		Date:			
	ompanying this transmission contain confidential				
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)					

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.